These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 33838223

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R, Estaitieh N, Mugharbil A, Jisr T, Abdallah DI, Ziade F, Sinno L, Ibrahim A.
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
    Gatti M, Raschi E, De Ponti F.
    Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1169-1176. PubMed ID: 33415492
    [Abstract] [Full Text] [Related]

  • 9. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R, Park TE, Moy S.
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime/avibactam and ceftolozane/tazobactam.
    Neves CS, Moura LCRV, Da Costa Lima JL, Maciel MAV.
    Braz J Microbiol; 2024 Mar; 55(1):333-341. PubMed ID: 38133795
    [Abstract] [Full Text] [Related]

  • 12. The use of new antibacterial drugs against infections caused by multidrug-resistant Gram-negative bacteria: an Italian real-world evidence study in a Lombardy hospital.
    Ferrara F, Pasquinucci R, Aloisi AC, Polito G, Bagaglini G, Capuozzo M, Zovi A.
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Oct; 397(10):8069-8075. PubMed ID: 38789634
    [Abstract] [Full Text] [Related]

  • 13. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
    Rando E, Novy E, Sangiorgi F, De Pascale G, Fantoni M, Murri R, Roberts JA, Cotta MO.
    Int J Antimicrob Agents; 2024 Sep; 64(3):107266. PubMed ID: 38971203
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
    Zhang F, Li P, Zhong J, Ding H, Liao G, Liang C.
    Front Cell Infect Microbiol; 2024 Sep; 14():1404404. PubMed ID: 38779560
    [Abstract] [Full Text] [Related]

  • 15. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J, Asar L, Klupp EM, Both A, Rothe C, König C, Rohde H, Kluge S, Maurer FP.
    PLoS One; 2018 Sep; 13(4):e0195757. PubMed ID: 29649276
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam.
    Hareza DA, Cosgrove SE, Bonomo RA, Dzintars K, Karaba SM, Hawes AM, Tekle T, Simner PJ, Tamma PD.
    Antimicrob Agents Chemother; 2024 Oct 08; 68(10):e0090724. PubMed ID: 39230311
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital.
    Poon LM, Jin J, Chee YL, Ding Y, Lee YM, Chng WJ, Chai LY, Tan LK, Hsu LY.
    Singapore Med J; 2012 Nov 08; 53(11):720-5. PubMed ID: 23192498
    [Abstract] [Full Text] [Related]

  • 18. Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.
    Clerici D, Galli L, Greco R, Lugli AP, Erbella F, Ripa M, Tassan Din C, Nitti R, Giglio F, Mastaglio S, Lorentino F, Xue E, Farina F, Liberatore C, Poli A, Carletti S, Lupo Stanghellini MT, Carrabba MG, Assanelli AA, Ruggeri A, Bernardi M, Corti C, Peccatori J, Mancini N, Scarpellini P, Ciceri F, Castagna A, Oltolini C.
    Blood Adv; 2023 May 09; 7(9):1621-1634. PubMed ID: 36409602
    [Abstract] [Full Text] [Related]

  • 19. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
    Rodriguez BA, Girotto JE, Nicolau DP.
    Curr Pediatr Rev; 2018 May 09; 14(2):97-109. PubMed ID: 29521242
    [Abstract] [Full Text] [Related]

  • 20. Ceftolozane/tazobactam and ceftazidime/avibactam antimicrobial activity against clinically relevant gram-negative bacilli isolated in Mexico.
    Martínez-Miranda R, Gastélum-Acosta M, Guerrero-Estrada P, Ayala-Figueroa RI, Osuna-Álvarez LE.
    Gac Med Mex; 2020 May 09; 156(6):592-597. PubMed ID: 33877120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.